INBX — Inhibrx Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology
$122.72
+$17.78 (+16.94%)
Inhibrx Biosciences, Inc. (INBX) is a biotechnology company listed on NASDAQ. It is led by Mark Paul Lappe, based in 11025 North Torrey Pines Road, La Jolla, CA, United States, 92037, with about 109 employees. Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Latest reported INBX revenue for 2025-09-30 was $0. Net income was -$35.3M. Revenue was down 100.0% from 2025-06-30 to 2025-09-30. INBX currently screens at market cap $1.28B.
Use this INBX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the INBX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the INBX SEC filings page. Lician reads the product cache first so this HTML stays unique to Inhibrx Biosciences, Inc. even when a live quote feed is slow.
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
INBX Key Statistics
Market Cap
$1.28B
Volume
509,419
Previous Close
$104.94
Day Range
$104.71 – $126.50
EPS
$112.62
Revenue
$200.00K
Net Income
$1.69B
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-88.9%
Profit Margin
843786.0%
Employees
109
INBX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 |
|---|---|---|
| Revenue | $200.00K | $1.80M |
| Cost of Revenue | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 |
| Net Income | $1.69B | -$241.36M |
| EPS (Diluted) | $112.62 | -$20.48 |
Total Assets
$180.77M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$152.60M
Operating Cash Flow
-$194.41M
Free Cash Flow
$0.00
Inhibrx Biosciences, Inc. Company Information
- Founder, CEO & Chairman
- Mark Paul Lappe
- Headquarters
- 11025 North Torrey Pines Road, La Jolla, CA, United States, 92037
- Website
- inhibrx.com
- Phone
- 858 795 4220
- IPO / Founded
- 2024-05-29
- Sector
- Healthcare
- Industry
- Biotechnology